Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Efgartigimod Alfa→

Efgartigimod Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1821402-21-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Neonatal Fc Receptor BlockerEndoglycosidaseGlycoside Hydrolases
Mechanism of action
Neonatal Fc Receptor Blockers [MoA]
Indications / reported uses
  • Myasthenia Gravis
  • adult patients with generalized myasthenia gravis (gMG)

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Efgartigimod Alfa Environmental Risk Assessment (ERA) (the Efgartigimod Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.